Body, Brain, Life for Cognitive Decline (BBL-CD): protocol for a multidomain dementia risk reduction randomized controlled trial for subjective cognitive decline and mild cognitive impairment

Mitchell McMaster, Sarang Kim, Linda Clare, Susan J Torres, Catherine D'Este, Kaarin J Anstey, Mitchell McMaster, Sarang Kim, Linda Clare, Susan J Torres, Catherine D'Este, Kaarin J Anstey

Abstract

Background: With no cure for dementia and the number of people living with the condition predicted to rapidly rise, there is an urgent need for dementia risk reduction and prevention interventions. Modifiable lifestyle risk factors have been identified as playing a major role in the development of dementia; hence, interventions addressing these risk factors represent a significant opportunity to reduce the number of people developing dementia. Relatively few interventions have been trialed in older participants with cognitive decline (secondary prevention).

Objectives: This study evaluates the efficacy and feasibility of a multidomain lifestyle risk reduction intervention for people with subjective cognitive decline (SCD) and mild cognitive impairment (MCI).

Methods: This study is an 8-week, two-arm, single-blind, randomized controlled trial (RCT) of a lifestyle modification program to reduce dementia risk. The active control group receives the following four online educational modules: dementia literacy and lifestyle risk, Mediterranean diet (MeDi), cognitive engagement and physical activity. The intervention group also completes the same educational modules but receives additional practical components including sessions with a dietitian, online brain training and sessions with an exercise physiologist to assist with lifestyle modification.

Results: Primary outcome measures are cognition (The Alzheimer's Disease Assessment Scale-Cognitive-Plus [ADAS-Cog-Plus]) and a composite lifestyle risk factor score for Alzheimer's disease (Australian National University - Alzheimer's Disease Risk Index [ANU-ADRI]). Secondary outcome measures are motivation to change lifestyle (Motivation to Change Lifestyle and Health Behaviour for Dementia Risk Reduction [MCLHB-DRR]) and health-related quality of life (36-item Short Form Health Survey [SF-36]). Feasibility will be determined through adherence to diet (Mediterranean Diet Adherence Screener [MEDAS] and Australian Recommended Food Score [ARFS]), cognitive engagement (BrainHQ-derived statistics) and physical activity interventions (physical activity calendars). Outcomes are measured at baseline, immediately post-intervention and at 3- and 6-month follow-up by researchers blind to group allocation.

Discussion: If successful and feasible, secondary prevention lifestyle interventions could provide a targeted, cost-effective way to reduce the number of people with cognitive decline going on to develop Alzheimer's disease (AD) and other dementias.

Keywords: Alzheimer’s disease; dementia prevention; dementia risk reduction; mild cognitive impairment; multidomain lifestyle intervention; secondary prevention; subjective cognitive decline.

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Timing of intervention components and testing periods.

References

    1. Alzheimer’s Disease International World Alzheimer’s Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends. 2015
    1. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–828.
    1. Fratiglioni L, Winblad B, von Strauss E. Prevention of Alzheimer’s disease and dementia. Major findings from the Kungsholmen Project. Physiol Behav. 2007;92(1–2):98–104.
    1. Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10(6):844–852.
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183–194.
    1. Mitchell AJ, Beaumont H, Ferguson D, Yadegarfar M, Stubbs B. Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis. Acta Psychiatr Scand. 2014;130(6):439–451.
    1. Amariglio RE, Becker JA, Carmasin J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia. 2012;50(12):2880–2886.
    1. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer’s disease. Brain. 2007;130(Pt 11):2837–2844.
    1. Shi F, Liu B, Zhou Y, Yu C, Jiang T. Hippocampal volume and asymmetry in mild cognitive impairment and Alzheimer’s disease: meta-analyses of MRI studies. Hippocampus. 2009;19(11):1055–1064.
    1. Perrotin A, de Flores R, Lamberton F, et al. Hippocampal subfield volumetry and 3D surface mapping in subjective cognitive decline. J Alzheimers Dis. 2015;48(s1):S141–S150.
    1. Bradfield NI, Ellis KA, Savage G, et al. Baseline amnestic severity predicts progression from amnestic mild cognitive impairment to Alzheimer disease dementia at 3 years. Alzheimer Dis Assoc Disord. 2018;32(3):190–196.
    1. Wallin A, Nordlund A, Jonsson M, et al. The Gothenburg MCI study: design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. J Cereb Blood Flow Metab. 2016;36(1):114–131.
    1. Malek-Ahmadi M. Reversion from mild cognitive impairment to normal cognition: a meta-analysis. Alzheimer Dis Assoc Disord. 2016;30(4):324–330.
    1. Xu W, Tan L, Wang HF, et al. Meta-analysis of modifiable risk factors for Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2015;86(12):1299–1306.
    1. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11(6):718–726.
    1. Davis C, Bryan J, Hodgson J, Murphy K. Definition of the Mediterranean diet; a literature review. Nutrients. 2015;7(11):9139–9153.
    1. Salas-Salvadó J, Becerra-Tomás N, García-Gavilán JF, Bulló M, Barrubés L. Mediterranean diet and cardiovascular disease prevention: what do we know? Prog Cardiovasc Dis. 2018;61(1):62–67.
    1. Berti V, Walters M, Sterling J, et al. Mediterranean diet and 3-year Alzheimer brain biomarker changes in middle-aged adults. Neurology. 2018;90(20):e1789–e1798.
    1. Luciano M, Corley J, Cox SR, et al. Mediterranean-type diet and brain structural change from 73 to 76 years in a Scottish cohort. Neurology. 2017;88(5):449–455.
    1. Pelletier A, Barul C, Féart C, et al. Mediterranean diet and preserved brain structural connectivity in older subjects. Alzheimers Dement. 2015;11(9):1023–1031.
    1. Rebok GW, Ball K, Guey LT. Ten-year effects of the ACTIVE cognitive training trial on cognition and everyday functioning in older adults. J Am Geriatr Soc. 2014;62(1):16.
    1. Edwards JD, Xu H, Clark D, Ross LA, Unverzagt FW. The ACTIVE study: what we have learned and what is next? Cognitive training reduces incident dementia across ten years. Alzheimer’s Dementia. 2016;12(7):P212.
    1. Lanier JB, Bury DC, Richardson SW. Diet and Physical activity for cardiovascular disease prevention. Am Fam Physician. 2016;93(11):919–924.
    1. Loprinzi PD, Frith E, Ponce P. Memorcise and Alzheimer’s disease. Phys Sportsmed. 2018;46(2):145–154.
    1. Ashby-Mitchell K, Burns R, Shaw J, Anstey KJ. Proportion of dementia in Australia explained by common modifiable risk factors. Alzheimers Res Ther. 2017;9(1):11.
    1. Horr T, Messinger-Rapport B, Pillai JA. Systematic review of strengths and limitations of randomized controlled trials for non-pharmacological interventions in mild cognitive impairment: focus on Alzheimer’s disease. J Nutr Health Aging. 2015;19(2):141–153.
    1. Smart CM, Karr JE, Areshenkoff CN, et al. Non-pharmacologic interventions for older adults with subjective cognitive decline: systematic review, meta-analysis, and preliminary recommendations. Neuropsychol Rev. 2017;27(3):245–257.
    1. Williams JW, Plassman BL, Burke J, Holsinger T, Benjamin S. Prevention Alzheimer’s Disease and Cognitive Decline. Rockville, MD: Agency for Healthcare Research and Quality (US); 2010.
    1. Fotuhi M, Lubinski B, Trullinger M, et al. A Personalized 12-week “Brain Fitness Program” for improving cognitive function and increasing the volume of hippocampus in elderly with mild cognitive impairment. J Prev Alzheimers Dis. 2016;3(3):133–137.
    1. Ling Ng TP, Feng AL, et al. Cognitive effects of multi-domain interventions among pre-frail and frail community-living older persons: randomized controlled trial. J Gerontol Series A. 2017
    1. Anstey KJ, Bahar-Fuchs A, Herath P, et al. Body brain life: a randomized controlled trial of an online dementia risk reduction intervention in middle-aged adults at risk of Alzheimer’s disease. Alzheimers Dement. 2015;1(1):72–80.
    1. Kim S, Mcmaster M, Torres S, et al. Protocol for a pragmatic randomised controlled trial of Body Brain Life-General Practice and a Lifestyle Modification Programme to decrease dementia risk exposure in a primary care setting. BMJ Open. 2018;8(3):e019329.
    1. Anstey KJ, Kim S, homepage on the Internet . The Body, Brain, Life-Fit (BBL-FIT) Program – A Pilot Study to Evaluate the Feasibility of the BBL-FIT Online Lifestyle Program in Middle-Aged Adults at Risk of Dementia (ACTRN12615000822583) Australian and New Zealand Clinical Trial Registry; 2015. [Accessed October 24, 2018]. Available from: .
    1. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191.
    1. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207.
    1. Australian Department of Health [homepage on the Internet] Physical Activity and Sendentary Behaviour Guidelines. Physical Activity and Sendentary Behaviour Guidelines. [Accessed 1/5/2018]. Available from: .
    1. Estruch R, Ros E, Salas-Salvadó J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279–1290.
    1. Posit Sceince [homepage on the Internet] BrainHQ; [Accessed October 3, 2018]. Available from: .
    1. Skinner J, Carvalho JO, Potter GG, et al. The Alzheimer’s Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain Imaging Behav. 2012;6(4):489–501.
    1. Kueper JK, Speechley M, Montero-Odasso M. The Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review. J Alzheimers Dis. 2018;63(2):423–444.
    1. Reitan RM. Trail Making Test: Manual for Administration and Scoring. Tucson, AZ: Reitan Neuropsychology Laboratory; 1992.
    1. Smith A. Symbol Digit Modalities Test. Los Angeles, CA: Western Psychological Services; 1982.
    1. Lucas JA, Ivnik RJ, Smith GE, et al. Mayo’s older Americans normative studies: category fluency norms. J Clin Exp Neuropsychol. 1998;20(2):194–200.
    1. Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323–329.
    1. Cano SJ, Posner HB, Moline ML, et al. The ADAS-cog in Alzheimer’s disease clinical trials: psychometric evaluation of the sum and its parts. J Neurol Neurosurg Psychiatry. 2010;81(12):1363–1368.
    1. Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer’s disease for use in population health approaches to prevention. Prev Sci. 2013;14(4):411–421.
    1. Anstey KJ, Cherbuin N, Herath PM, et al. A self-report risk index to predict occurrence of dementia in three independent cohorts of older adults: the ANU-ADRI. PLoS One. 2014;9(1):e86141.
    1. Kim S, Sargent-Cox K, Cherbuin N, Anstey KJ. Development of the motivation to change lifestyle and health behaviours for dementia risk reduction scale. Dement Geriatr Cogn Dis Extra. 2014;4(2):172–183.
    1. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483.
    1. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–292.
    1. Gibson RS. Principles of Nutritional Assessment. 2nd ed. New York: Oxford University Press; 2005.
    1. Schröder H, Fitó M, Estruch R, et al. A short screener is valid for assessing Mediterranean diet adherence among older Spanish men and women. J Nutr. 2011;141(6):1140–1145.
    1. Collins CE, Burrows TL, Rollo ME, et al. The comparative validity and reproducibility of a diet quality index for adults: the Australian Recommended Food Score. Nutrients. 2015;7(2):785–798.
    1. National Health and Medical Research Council Australian Dietary Guidleines. [Accessed on 10 May 2018]. 2013. Available from: .
    1. National Health and Medical Research Council . Australian Guide to Healthy Eating. Canberra: National Health and Medical Research Council; 2003.
    1. Borg G. Borg’s Perceived Exertion and Pain Scales. Champaign, IL: Human kinetics; 1998.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj